Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03026166 · ClinicalTrials.gov registry record · Phase 1
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03026166 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 42 participants.
The verdict
NCT03026166, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Rovalpituzumab tesirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2019-07-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03026166
The ClinicalTrials.gov registry entry for NCT03026166 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03026166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03026166 about?
NCT03026166 is a clinical study titled "A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer". The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).
What is the current status of trial NCT03026166?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2017-03-30. Estimated completion is 2019-07-03.
What interventions are being tested in trial NCT03026166?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Rovalpituzumab tesirine (DRUG).
Who is sponsoring clinical trial NCT03026166?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.